Abstract
Background
This retrospective study aimed to determine the long-term effects and toxicity of a combined chemotherapeutic regimen of gemcitabine and cisplatin (GC) in the treatment of metastatic urothelial carcinomas (UCs).
Methods
Seventy-one patients with metastatic UC were treated with GC (gemcitabine 1000 mg/m2 on days 1, 8, and 15 and cisplatin 70 mg/m2 on day 2 every 28 days). The patients were divided into 3 groups: patients who had not undergone prior chemotherapy (group 1), patients who relapsed more than 6 months after being treated with the prior cisplatin-based regimen (group 2), and patients in whom the prior cisplatin-based regimen demonstrated no effect (group 3). The median follow-up was 42 months.
Results
In group 1, 20 of the 32 patients (63%) showed an objective response, with 6 achieving a clinically complete response (CR) and 14 a partial response (PR) with GC. Ten of 32 patients (31%) and 1 of 7 patients (14%) showed objective responses in groups 2 and 3, respectively. Patients in group 2 who had previously been treated with regimens other than GC showed a better objective response (58%) than those with GC (15%). The median time to progression in group 1 was 6 months, and the median overall survival was 14 months. In all, the nonhematological toxicities associated with GC were quite mild. Grade 3–4 toxicity was primarily hematological, including anemia (19%), neutropenia (36%), and thrombocytopenia (42%).
Conclusions
GC is therefore considered to be a highly effective and well-tolerated regimen with moderate toxicity for the treatment of metastatic UCs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Saxman SB, Proper KJ, Einhorn LH et al (1997) Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15:2564–2569
Bajorin DF, Dodd PM, Mazumdar M et al (1999) Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173–3181
Roth BJ, Bajorin D (1995) Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). World J Urol 153:894–900
von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 17:3068–3077
Kaufman D, Raghavan D, Carducci M et al (2000) Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 18:1921–1927
Moore MJ, Winquist E, Murray N et al (1999) Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a Phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17:2876–2880
Ozawa A, Tanji N, Ochi T et al (2007) Gemcitabine and cisplatin for advanced urothelial carcinomas: the Ehime University Hospital experience. Int J Clin Oncol 12:279–283
von der Maase H, Sengelov L, Roberts JT et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602–4608
Suyama T, Ueda T, Fukasawa S et al (2009) Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma. Jpn J Clin Oncol 39:244–250
Shinohara N, Harabayashi T, Suzuki S et al (2006) Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy. Cancer Chemother Pharmacol 58:402–407
Barlesi F, Villani P, Doddoli C et al (2004) Gemcitabine-induced severe pulmonary toxicity. Fundam Clin Pharmacol 18:85–91
Conflict of interest statement
N. Tanji received honoraria for lectures from Eli Lilly Japan K.K. Other authors have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Tanji, N., Ozawa, A., Miura, N. et al. Long-term results of combined chemotherapy with gemcitabine and cisplatin for metastatic urothelial carcinomas. Int J Clin Oncol 15, 369–375 (2010). https://doi.org/10.1007/s10147-010-0069-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-010-0069-2